Trial Profile
Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Alkylating agents
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 07 Dec 2015 New trial record